167 related articles for article (PubMed ID: 30199249)
1. Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N
Woodward HL; Innocenti P; Cheung KJ; Hayes A; Roberts J; Henley AT; Faisal A; Mak GW; Box G; Westwood IM; Cronin N; Carter M; Valenti M; De Haven Brandon A; O'Fee L; Saville H; Schmitt J; Burke R; Broccatelli F; van Montfort RLM; Raynaud FI; Eccles SA; Linardopoulos S; Blagg J; Hoelder S
J Med Chem; 2018 Sep; 61(18):8226-8240. PubMed ID: 30199249
[TBL] [Abstract][Full Text] [Related]
2. Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach.
Innocenti P; Woodward HL; Solanki S; Naud S; Westwood IM; Cronin N; Hayes A; Roberts J; Henley AT; Baker R; Faisal A; Mak GW; Box G; Valenti M; De Haven Brandon A; O'Fee L; Saville H; Schmitt J; Matijssen B; Burke R; van Montfort RL; Raynaud FI; Eccles SA; Linardopoulos S; Blagg J; Hoelder S
J Med Chem; 2016 Apr; 59(8):3671-88. PubMed ID: 27055065
[TBL] [Abstract][Full Text] [Related]
3. High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers.
Anderhub SJ; Mak GW; Gurden MD; Faisal A; Drosopoulos K; Walsh K; Woodward HL; Innocenti P; Westwood IM; Naud S; Hayes A; Theofani E; Filosto S; Saville H; Burke R; van Montfort RLM; Raynaud FI; Blagg J; Hoelder S; Eccles SA; Linardopoulos S
Mol Cancer Ther; 2019 Oct; 18(10):1696-1707. PubMed ID: 31575759
[TBL] [Abstract][Full Text] [Related]
4. Studies of Interaction Mechanism between Pyrido [3,4-
Xing C; Zhou X; Chen C; Sun W; Zheng Q; Liang D
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443663
[TBL] [Abstract][Full Text] [Related]
5. A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity.
Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Kojima E; Mitsuoka Y; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Yoshizawa H; Murai H; Nakamura Y
Bioorg Med Chem; 2015 May; 23(9):2247-60. PubMed ID: 25801152
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
[TBL] [Abstract][Full Text] [Related]
8. Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.
Schulze VK; Klar U; Kosemund D; Wengner AM; Siemeister G; Stöckigt D; Neuhaus R; Lienau P; Bader B; Prechtl S; Holton SJ; Briem H; Marquardt T; Schirok H; Jautelat R; Bohlmann R; Nguyen D; Fernández-Montalván AE; Bömer U; Eberspaecher U; Brüning M; Döhr O; Raschke M; Kreft B; Mumberg D; Ziegelbauer K; Brands M; von Nussbaum F; Koppitz M
J Med Chem; 2020 Aug; 63(15):8025-8042. PubMed ID: 32338514
[TBL] [Abstract][Full Text] [Related]
9. Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.
Anderson K; Chen Y; Chen Z; Dominique R; Glenn K; He Y; Janson C; Luk KC; Lukacs C; Polonskaia A; Qiao Q; Railkar A; Rossman P; Sun H; Xiang Q; Vilenchik M; Wovkulich P; Zhang X
Bioorg Med Chem Lett; 2013 Dec; 23(24):6610-5. PubMed ID: 24239188
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1).
Naud S; Westwood IM; Faisal A; Sheldrake P; Bavetsias V; Atrash B; Cheung KM; Liu M; Hayes A; Schmitt J; Wood A; Choi V; Boxall K; Mak G; Gurden M; Valenti M; de Haven Brandon A; Henley A; Baker R; McAndrew C; Matijssen B; Burke R; Hoelder S; Eccles SA; Raynaud FI; Linardopoulos S; van Montfort RL; Blagg J
J Med Chem; 2013 Dec; 56(24):10045-65. PubMed ID: 24256217
[TBL] [Abstract][Full Text] [Related]
11. X-ray Crystal Structure-Guided Design and Optimization of 7
Lee Y; Kim H; Kim H; Cho HY; Jee JG; Seo KA; Son JB; Ko E; Choi HG; Kim ND; Kim I
J Med Chem; 2021 May; 64(10):6985-6995. PubMed ID: 33942608
[TBL] [Abstract][Full Text] [Related]
12. Novel Mps1 kinase inhibitors: from purine to pyrrolopyrimidine and quinazoline leads.
Bursavich MG; Dastrup D; Shenderovich M; Yager KM; Cimbora DM; Williams B; Kumar DV
Bioorg Med Chem Lett; 2013 Dec; 23(24):6829-33. PubMed ID: 24183538
[TBL] [Abstract][Full Text] [Related]
13. Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.
Wengner AM; Siemeister G; Koppitz M; Schulze V; Kosemund D; Klar U; Stoeckigt D; Neuhaus R; Lienau P; Bader B; Prechtl S; Raschke M; Frisk AL; von Ahsen O; Michels M; Kreft B; von Nussbaum F; Brands M; Mumberg D; Ziegelbauer K
Mol Cancer Ther; 2016 Apr; 15(4):583-92. PubMed ID: 26832791
[TBL] [Abstract][Full Text] [Related]
14. Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective.
Wang S; Zhang M; Liang D; Sun W; Zhang C; Jiang M; Liu J; Li J; Li C; Yang X; Zhou X
Eur J Med Chem; 2019 Aug; 175():247-268. PubMed ID: 31121430
[TBL] [Abstract][Full Text] [Related]
15. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of a new class of 7H-pyrrolo[2,3-d]pyrimidine derivatives as Mps1 inhibitors for the treatment of breast cancer.
Li X; Wei W; Tao L; Zeng J; Zhu Y; Yang T; Wang Q; Tang M; Liu Z; Yu L
Eur J Med Chem; 2023 Jan; 245(Pt 1):114887. PubMed ID: 36370549
[TBL] [Abstract][Full Text] [Related]
17. Characterization of novel MPS1 inhibitors with preclinical anticancer activity.
Jemaà M; Galluzzi L; Kepp O; Senovilla L; Brands M; Boemer U; Koppitz M; Lienau P; Prechtl S; Schulze V; Siemeister G; Wengner AM; Mumberg D; Ziegelbauer K; Abrieu A; Castedo M; Vitale I; Kroemer G
Cell Death Differ; 2013 Nov; 20(11):1532-45. PubMed ID: 23933817
[TBL] [Abstract][Full Text] [Related]
18. TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.
Choi M; Min YH; Pyo J; Lee CW; Jang CY; Kim JE
Br J Pharmacol; 2017 Jun; 174(12):1810-1825. PubMed ID: 28299790
[TBL] [Abstract][Full Text] [Related]
19. Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.
Laufer R; Ng G; Liu Y; Patel NK; Edwards LG; Lang Y; Li SW; Feher M; Awrey DE; Leung G; Beletskaya I; Plotnikova O; Mason JM; Hodgson R; Wei X; Mao G; Luo X; Huang P; Green E; Kiarash R; Lin DC; Harris-Brandts M; Ban F; Nadeem V; Mak TW; Pan GJ; Qiu W; Chirgadze NY; Pauls HW
Bioorg Med Chem; 2014 Sep; 22(17):4968-97. PubMed ID: 25043312
[TBL] [Abstract][Full Text] [Related]
20. Hijacking monopolar spindle 1 (MPS1) for various cancer types by small molecular inhibitors: Deep insights from a decade of research and patents.
Liang C; Zhou Y; Xin L; Kang K; Tian L; Zhang D; Li H; Zhao Q; Gao H; Shi Z
Eur J Med Chem; 2024 Jul; 273():116504. PubMed ID: 38795520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
